CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1

Area of Science:

• Immunology
• Cardiovascular Biology
• Molecular Medicine

Background:

• CD40 ligand (CD40L) is a marker and mediator of inflammatory diseases like atherosclerosis.
• The role of CD40, the classic CD40L receptor, in immune defense against inflammatory diseases is not fully understood.
• CD40 signaling's contribution to atherogenesis requires further characterization.

Purpose of the Study:

• To investigate the role of CD40 signaling in the development of atherosclerosis.
• To identify alternative pathways for CD40L-mediated inflammation.
• To elucidate the molecular mechanisms underlying CD40L's involvement in inflammatory diseases.

Main Methods:

• Utilized mouse models deficient in CD40 and low-density lipoprotein receptor (LDLR).
• Employed flow cytometry, radioactive binding assays, and immunoprecipitation to study CD40L interactions.
• Assessed inflammatory cell infiltration and myeloperoxidase release in vitro and in vivo.
• Investigated the effect of Mac-1 inhibition on lesion development in LDLR-deficient mice.

Main Results:

• Mice lacking both CD40 and LDLR did not show smaller atherosclerotic lesions compared to LDLR-deficient mice.
• CD40L was found to interact with the integrin Mac-1, mediating inflammatory cell adhesion, migration, and myeloperoxidase release.
• CD40L-deficient mice exhibited reduced inflammatory cell invasion into the peritoneal cavity.
• Inhibition of Mac-1 attenuated lesion development and reduced macrophage accumulation in LDLR-deficient mice.

Conclusions:

• Identified a novel pathway where CD40L interacts with Mac-1, contributing to CD40L-mediated inflammation.
• This CD40L-Mac-1 interaction represents an alternative inflammatory signaling mechanism.
• The findings expand the understanding of inflammatory signaling in the context of atherogenesis.